How it works:
Inhibits proliferation of cancer cells
Stimulates immune response against malignant cells
Reduces blood vessel formation in tumours (antiangiogenic effect)
Helps reduce anaemia in patients with del(5q) MDS
Recommended for:
Patients with multiple myeloma
For MDS with chromosome 5q deletion
For mantle cell lymphoma
As prescribed by an oncologist for other blood malignancies
Treatment of multiple myeloma (in combination therapy), myelodysplastic syndromes with 5q deletion, and mantle cell lymphoma.
LENASAB is taken orally once daily at the same time each day. Dosage is strictly determined by the treating physician based on the patient’s condition, weight and tolerance. Regular monitoring is required for safety and blood counts.
Contraindications:
Pregnancy and planning pregnancy
Hypersensitivity to lenalidomide
Lactase deficiency, galactosaemia
Severe liver or kidney impairment
Age under 18
Side effects:
Neutropenia, thrombocytopenia
Nausea, constipation, diarrhoea
Fatigue
Rash, itching
Increased risk of blood clots
Liver dysfunction
